ASTHMA AND CHRONIC OBSTRUCTIVE pulmonary disease (COPD) are chronic respiratory disorders both with the key characteristics of airway smooth muscle cell (ASMC) hyperplasia and hypertrophy within the airway walls (3, 11, 39) . Thicker ASMC bundles have the pathological effect of narrowing the luminal area causing obstruction to breathing. In asthma, the resultant increase in ASMC can enhance contraction in response to stimuli by amplifying the extent of narrowing (28, 32) .
The increased number of ASMC in asthma and COPD may be due to greater cellular proliferation of asthmatic ASMC (20) , potentially driven by exposure of ASMC to cigarette smoke inducing ASMC proliferation (37) . In addition, ASMC are capable of migrating in the lung (35) , particularly in response to chemokines (43) and allergic stimuli (41) . Thus it is possible that both processes of migration and proliferation may act together to increase ASMC mass in the lungs.
The extracellular matrix (ECM) is an acellular scaffold, made up of numerous different proteins, that surrounds and supports cells in the lungs. It has been known for some time that the ECM is altered in the airway walls of patients with asthma (1, 10a) and COPD (23, 25) . Perlecan is an ECM glycoprotein ubiquitously expressed in basement membranes throughout the body (29) , and in vivo studies (10) have demonstrated that deposition of perlecan in the airway wall is enhanced in asthma. Perlecan is a large molecule made up of five-core domain proteins (I-V), each with different biological properties. In other organ systems, the different domains of the perlecan molecule play roles in cell adhesion (17, 38) , angiogenesis (40, 46) , tumor pathogenesis (15, 45) , and cellular proliferation 1 (5, 26, 44) . As research continues to highlight the bioactive role of the ECM, we sought to investigate the role of perlecan in asthma and COPD. This study aimed to investigate mechanisms by which deposition of perlecan may be upregulated from ASMC, if perlecan deposition differs between ASMC obtained from donors with different lung diseases, and whether different domains of the perlecan molecule can influence the behavior of ASMC. We hypothesized that the profibrotic cytokine transforming growth factor-␤ 1 (TGF-␤ 1 ), which has increased expression in asthma (30) , would upregulate production of perlecan from ASMC via activation of intracellular signaling molecules and that perlecan would in turn influence ASMC attachment and proliferation.
METHODS
Subjects. ASMC were isolated from human airway samples obtained via lung resection, transplantation or bronchial biopsies from n ϭ 13 donors with asthma, n ϭ 12 with COPD, and n ϭ 20 with lung disease that was neither asthma nor COPD. The diagnosis of disease was made by thoracic physicians according to current guidelines. All donors gave written, informed consent. Approval for all experiments with human lung was provided by the Human Ethics Committees of the University of Sydney and the Sydney South West Area Health Service. Individual donor details, where available, are provided in Table 1 .
Cell culture. Pure ASM bundles were dissected free and grown as previously described (20) . ASMC characterization was confirmed by means of light microscopy to assess morphological hill-and-valley characteristics and immunohistochemistry for smooth muscle ␣-actin and calponin expression (20) . All experiments were performed with cells between passages 4 and 8, during which the ASMC maintained their characteristics in vitro and the capacity to produce ECM proteins, as previously published (18) .
Cytokine stimulation. ASMC were stimulated with 1 ng/ml TGF-␤ 1 (R&D Systems, Minneapolis, MN) for 48 h before ECM free of cells was prepared by treatment with sterile hypotonic ammonium hydroxide as previously described (18, 24) .
Analysis of perlecan deposition by ECM ELISA.
Perlecan deposition into the ECM was measured by a novel ECM ELISA using monoclonal mouse-anti human perlecan antibodies (Zymed, Carlsbad, CA), as previously described (24) .
Signaling inhibition. ASMC were seeded in 96-well plates for 72 h in 5% FBS/antibiotics/DMEM at a density of 3.2 ϫ 10 4 cells/cm 2 . Cells were equilibrated for 24 h in 0.1% (vol/vol) FBS/antibiotics/ DMEM before incubation in the presence of SB431542 (3 and 10 M; Cayman Chemicals, Ann Arbor, MI), PD98059 (1 and 10 M), LY294002 (1, 3, and 10 M) (Calbiochem, San Diego, CA), SB293063 (1 and 3 M; Tocris, Ellisville, MI), or SP600125 (1 and 10 M; A. G. Scientific, San Diego, CA) in appropriate concentrations of DMSO in 0.1% FBS/antibiotics/DMEM. After 1 h, media were aspirated before the addition of TGF-␤ 1 (1 ng/ml) alone and in the presence of the inhibitors for 48 h. In some experiments, total protein was collected after 2-h stimulation for analysis via Western blotting.
Western blotting. Assessment of protein phosphorylation following stimulation with TGF-␤ 1 (1 ng/ml) alone and in the presence of inhibitors of signaling molecules was performed using western blotting. Primary antibodies and their dilutions are as follows; c-Jun N-terminal kinase (JNK; 1:1,000), phospho-JNK (1: 1,000), Smad2/3 (1:1,000), or phospho-Smad2/3 (1:1,000). Blots were washed with TBS ϩ 0.05% Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibodies to rabbit (1:1,000) or mouse (1:5,000). Blots were detected using SuperSignal luminescence buffer and imaged with Kodak Image Station Camera and software. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; M, male; F, female; T, transplant; R, resection; B, bronchoscopy; ␣1, ␣1-antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; SCCa, small cell carcinoma; Ca, carcinoma; IPF, idiopathic pulmonary fibrosis; NSCCa, nonsmall cell carcinoma; Y, yes; N, no; N/A, not available. For experiments, 1: perlecan deposition and IL-6 release; 2: inhibition of signaling molecules; 3: attachment assays; 4: proliferation assays; 5: Western blotting; and 6: wound healing assays.
Attachment assay. The 96-well plates were coated with sterile perlecan domains I-V (AusPep, Victoria, Australia) at 10 g/ml, or rat-tail collagen domain I at 1 g/ml in PBS, as a positive control, for 24 h at 4°C. One hundred and fifty microliters per well of sterile 1% BSA/PBS were added to each well to block nonspecific binding for 1 h. After blocking solution was aspirated, ASMC were seeded at 3.2 ϫ 10 4 cells/cm 2 in 0.1% BSA/DMEM for 2 h at 37°C in 5% CO2. Media were then removed, and plates were washed three times with sterile PBS to remove any unattached cells before cells were fixed with 50 l/well 4% paraformaldehyde for 5 min. Cells were stained with 0.5% toluidine blue solution for 5 min before being washed three times with Milli-Q water. Cells were solublized by the addition of 1% SDS in Milli-Q for 30 min before absorbance was read at 595 nm using Wallac-1,000 plate reader and software (PerkinElmer).
Proliferation assay. ASMC were seeded on perlecan-coated plates, as described above, at 3.2 ϫ 10 4 cells/cm 2 in 5% FBS/antibiotics/ DMEM for 24, 48, and 72 h at 37°C in 5% CO2. Proliferation was assessed using a commercially available 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay according to the manufacturer's instructions (Sigma, St Louis, MI).
IL-6 and IL-8 ELISA. ASMC were seeded on perlecan-coated plates, as described above, at 3.2 ϫ 10 4 cells/cm 2 in 5% FBS/ antibiotics/DMEM for 48 h at 37°C in 5% CO2 before supernatants were collected and stored at Ϫ20°C. Concentration of IL-6 and IL-8 in the supernatants was analyzed using commercially available ELISA kits according to the manufacturer's instructions (R&D Systems).
Wound healing assay. Assessment of wound healing was performed using an Oris universal cell migration assembly kit according to the manufacturer's instructions (Platypus Technology, Madison, WI). Briefly, ASMC were seeded on perlecan peptide-coated Oris migration plates at 3.2 ϫ 10 4 cells/cm 2 in 5% FBS/antibiotics/DMEM for 48 h at 37°C in 5% CO2 before the removal of inserts to create the wound. After the plates were gently washed twice, media were replaced with 10% FBS/antibiotics/DMEM to stimulate wound healing, which was visualized over 36 h using a Nikon Elipse TI timelapse microscope with NIS-Elements AR 3.2 software (Nikon, Tokyo, Japan). Data analysis. Perlecan deposition was corrected by subtracting the absorbance reading of no-cell, negative control wells from the ASMC containing wells to remove background absorbance. Statistical analysis of the effect of TGF-␤ 1 on perlecan deposition was then performed by two-way repeated-measures ANOVA with Bonferroni posttests comparing control with TGF-␤1 for each group.
Statistical analysis of the effect of TGF-␤1 on IL-6 release was performed by two-way repeated measures ANOVA with Bonferroni posttests comparing control with TGF-␤1 for each group. To examine if there were differences in IL-6 release between disease groups, two-way repeated measures ANOVA was performed comparing asthma and COPD and nonasthma, non-COPD groups for differences in IL-6 release following incubation either in control media or in the presence of TGF-␤ 1. When comparing the effect of inhibition of signaling molecules on perlecan deposition, data were assessed for normality via D=Agostino and Person omnibus normality test and Kolmogorov-Smirnov tests. Differences between TGF-␤ 1-induced perlecan deposition from cells, with the addition of signaling inhibitors, was compared with vehicle control and assessed by paired, two-tailed, t-tests.
Differences in attachment of ASMC to perlecan domains was assessed by two-way repeated-measures ANOVA with Bonferroni posttests comparing attachment to perlecan domains with attachment to PBS and collagen I for each group.
All data were collated using Microsoft Excel Software and analysed using GraphPad Prism 5.0 (GraphPad, La Jolla, CA). Differences were considered significant when P Ͻ 0.05.
RESULTS

TGF-␤ 1 upregulates deposition of perlecan from COPD ASM.
Before stimulation, similar levels of perlecan were deposited from all ASMC groups (Fig. 1) . Following 48 h stimulation with 1 ng/ml TGF-␤ 1 , the deposition of perlecan was significantly upregulated from ASMC obtained from donors with COPD (P Ͻ 0.05; n ϭ 6). Deposition of perlecan by ASMC obtained from asthmatic and nonasthma-non-COPD donors was not changed by 1 ng/ml TGF-␤ 1 (n ϭ 6; Fig. 1 ).
TGF-␤ 1 upregulates IL-6 release from ASMC regardless of disease type. As there were differences between cell types in the ability to deposit perlecan following TGF-␤ 1 stimulation, we looked at the release of the cytokine IL-6 from ASMC to ensure that TGF-␤ 1 was functional and that the cells were capable of protein production. All three cell types significantly increased release of IL-6 following stimulation with 1 ng/ml TGF-␤ 1 (P Ͻ 0.05; n ϭ 6 for each cell type; Fig. 2 ), indicating that all cells were capable of responding to TGF-␤ 1 . Baseline release of IL-6 from ASMC derived from asthmatic donors was significantly greater than basal IL-6 release from donors with COPD or non-asthma, non-COPD (P Ͻ 0.05).
Inhibitors of SMAD and JNK signaling molecules decrease TGF-␤ 1 -induced perlecan deposition from ASMC. As TGF-␤ 1 induced perlecan deposition from only COPD ASMC, we then assessed the intracellular signaling mechanisms behind this induction in COPD ASMC. The JNK inhibitor SP600125 significantly decreased TGF-␤ 1 -induced perlecan deposition from COPD-derived ASMC (P Ͻ 0.05; n ϭ 6; Fig. 3A ). The addition of the SMAD signaling inhibitor SB431542 significantly decreased TGF-␤ 1 -induced perlecan deposition from COPD (P Ͻ 0.05; n ϭ 6)-derived ASMC (Fig. 3B ). Addition Fig. 1 . Deposition of perlecan from airway smooth muscle cells (ASMC) derived from donors with asthma (n ϭ 6), chronic obstructive pulmonary disease (COPD; n ϭ 6), or nonasthma, non-COPD (n ϭ 6) following 48-h stimulation with transforming growth factor-␤ (TGF-␤; 1 ng/ml). Columns represent mean absorbance at 405 nm less absorbance of the negative control (media alone). Error bars represent SE. OD, optical density. *P Ͻ 0.05, compared with unstimulated control. Fig. 2 . Release of IL-6 from ASMC derived from donors with asthma (n ϭ 6), COPD (n ϭ 6), or nonasthma, non-COPD (n ϭ 6) following 48-h stimulation with TGF-␤ (1 ng/ml). Columns represent mean concentration of IL-6 in pg/ml. Error bars represent SE. *P Ͻ 0.05, compared with unstimulated control.
of the p38 signaling inhibitor SB239063, the ERK signaling inhibitor PD98059, or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 had no effect on TGF-␤ 1 -induced perlecan deposition (Fig. 3, C-E) .
SMAD phosphorylation induced by TGF-␤ 1 in COPD ASMC is attenuated by SB431542. To assess if the observed differences were a result of differences in SMAD and JNK activation between ASMC groups following stimulation with TGF-␤ 1 , we performed Western blotting to assess relative levels of SMAD and JNK phosphorylation. TGF-␤ 1 (1 ng/ml) significantly upregulated SMAD phosphorylation in COPD ASMC following 2-h stimulation (P Ͻ 0.05; n ϭ 5; Fig. 4A) ; however, the differences were not significant for other ASMC types. In contrast, phosphorylation of JNK was not significantly upregulated by TGF-␤ 1 for any cell type (Fig. 4B) .
As the addition of SB431542 decreased TGF-␤ 1 -induced perlecan deposition from COPD ASMC, we assessed the role of SB431542 on attenuating SMAD phosphorylation in this cell type by Western blotting. The addition of SB431542 significantly attenuated SMAD phosphorylation induced by 1 ng/ml TGF-␤ 1 (P Ͻ 0.05; n ϭ 4; Fig. 5) .
Perlecan domains II, IV, and V increase ASMC attachment. To assess whether ASMC were able to bind to isolated ECM proteins, collagen domain I was used as a positive control and this significantly increased the attachment of nonasthma-non-COPD (P Ͻ 0.05; n ϭ 5), COPD ASMC (P Ͻ 0.05; n ϭ 8), and asthmatic ASMC (P Ͻ 0.05; n ϭ 5; Fig. 6 ). There were no differences in attachment to collagen domain I between the different cell types. Perlecan domain II (10 g/ml) only increased attachment of asthmatic ASMC (P Ͻ 0.05; n ϭ 5) but had no effect on attachment of ASMC from other donors (Fig.  6 ). Perlecan domains IV and V (10 g/ml) increased attachment of ASMC only from COPD donors (P Ͻ 0.05; n ϭ 8) but had no effect on ASMC from other donors. Perlecan domains I and III had no effect on attachment of ASMC regardless of subject characteristics.
Perlecan domains do not alter ASMC proliferation, wound healing, or cytokine release. Perlecan domains I-V had no effect on the proliferation of ASMC from any disease group (Fig. 7 ). There were no differences in the rate of wound healing of any ASMC type when plated on perlecan domains I-V (Fig. 8) . Seeding ASMC on perlecan domains I-V for 48 h had no effect on the release of IL-6 or IL-8 (Fig. 9) .
DISCUSSION
In this study, we examined the deposition of the ECM protein perlecan in response to stimulation with TGF-␤ 1 and found that TGF-␤ 1 induced the deposition of perlecan by ASMC from donors with COPD but not with asthma or neither disease. The upregulation of perlecan from COPD donors was mediated via SMAD and JNK intracellular signaling pathways. To explore if this increased deposition of perlecan could be functionally important in airway remodeling, we measured ASMC attachment to the different perlecan domains and found that perlecan domains II, IV, and V can mediate attachment of ASMC in different disease groups.
It is known that TGF-␤ 1 is upregulated in chronic lung disease (30) and is viewed by many groups as a primary cause of airway remodeling in airways disease as TGF-␤ 1 has been previously demonstrated to promote production of ECM proteins (2, 9, 31) from ASMC.
We observed the increase in perlecan deposition only in ASMC derived from COPD donors and that SMAD activation was upregulated in COPD ASMC to a greater extent than other cell types.
The enhanced upregulation of perlecan from COPD ASMC suggests that these ASMC may either be more sensitive to TGF-␤ 1 or may have an enhanced ability to upregulate perlecan production. By measuring IL-6 release following TGF-␤ 1 stimulation , we demonstrated that all cell types were able to upregulate IL-6 to a similar extent. This suggests that COPD ASMC are not generally more sensitive to TGF-␤ 1 compared with donors with asthma or neither lung disease but rather that COPD ASMC have an enhanced ability to produce perlecan. The reason why COPD ASMC produces more perlecan might be related to airway remodeling in vivo. Airway remodeling is a feature of both asthma and COPD, and while a plethora of studies exist demonstrating the changes that exist compared with nondiseased groups, very few studies directly compare asthma to COPD. In a recent study from Liesker et al. (25) , basement membrane thickness in asthma and COPD was compared. They found similar thickening of the basement membrane in the two diseases compared with the nondiseased group; however, they demonstrated that the ECM composition of the basement membrane was different. The levels of perlecan were not assessed in this study, and in fact no studies have directly compared airway perlecan composition between asthma and COPD. Nevertheless, since ASM hypertrophy and alterations in the ECM occur in both asthma and COPD (11, 16, 25) , it is plausible that the perlecan content surrounding the ASM is also altered.
TGF-␤ 1 -induced perlecan deposition from COPD ASMC was partially attenuated by inhibiting the SMAD and JNK intracellular signaling pathways. It has been shown that TGF-␤ 1 strongly induces phosphorylation of PI3K, p38 and, to a lesser extent, JNK and ERK (8, 42) signaling molecules in ASMC and that TGF-␤ 1 -induced proliferation and VEGF release are attenuated by inhibiting PI3K and ERK but not by inhibiting JNK (8, 42) . Our findings suggest that perlecan deposition by COPD ASM occurs by different signaling mechanisms to cytokine release, as SMAD and JNK inhibition attenuated TGF-␤ 1 perlecan deposition, whereas inhibiting PI3K, p38, and ERK had no effect. Phosphorylation of JNK was observed in unstimulated cells in this study but was not significantly induced by TGF-␤ 1 . This supports previous findings by our group, using epithelial cells, that TGF-␤ 1 induces the activation of SMAD but not JNK (14) .
The attenuation of perlecan deposition observed following the addition of the JNK inhibitor SP600125 may be due to the effect of SP600125 inhibiting the constitutive JNK phosphorylation. Alternatively, the attenuation of perlecan may be due to an effect of JNK inhibition on the considerable cross talk that occurs between the JNK and SMAD pathways (12, 33) . Thus by attenuating constitutive JNK activation, SP600125 may also be indirectly altering downstream SMAD signaling.
Whether increased perlecan deposition via SMAD activation is an innate characteristic of ASMC preceding development of COPD or is a result of prolonged exposure to cigarette smoke or other inhaled irritants is outside the scope of this study.
The effect of perlecan on ASMC is unknown. The role of perlecan in regulating activities of endothelium-derived smooth muscle cells has been documented in a number of studies (22, 40, 44) ; however, the effect of perlecan on ASMC has not been studied before.
An increase in ASMC attachment to ECM proteins produced in the airway wall of the lung may enhance the ability of migrating or newly replicated ASMC to attach to ASMC bundles within the airway wall, thus contributing to the thickening of the ASMC bundles observed in airways disease (3, 11) . In our study, all cell types adhered to collagen I to a similar extent but not to the different domains of perlecan. This indicates that binding of ASMC to different ECM proteins occurs in a specific manner, potentially mediated via different mechanisms.
It was unexpected to see exclusive attachment of asthmatic ASMC to perlecan domain II. Perlecan domain II binds con- nective tissue growth factor (CTGF; Ref. 34) , and the enhanced binding of asthmatic ASMC to domain II may be due to interactions between domain II and the enhanced CTGF expressed by asthmatic ASMC (6) or it may be due to altered integrin expression, as we (31) have previously shown that asthmatic ASMC express different integrins. To our knowledge, the expression of CTGF, or integrin profiles, of COPD and asthmatic ASMC has not been compared.
Perlecan domain IV has a well-documented role in attachment and spreading in multiple cell lines (13, 37) . Domain IV binds ligands such as fibronectin and collagen IV (29) , which are expressed on the ASMC surface (7, 19) , so it is likely that the increased attachment of COPD ASMC to perlecan domain IV is due to interactions between these ligands and the domain itself. In addition, the differences in attachment to domain IV between asthmatic and COPD ASMC may be related to the decreased levels of collagen IV in asthmatic airways (4, 5, 19) . ASMC-surface fibronectin is also upregulated by TGF-␤ 1 (31) ; thus it is reasonable to speculate that the increased TGF-␤ 1 expression in the airways of people with COPD may promote ASM attachment by two mechanisms; firstly, by having increased perlecan expression from resident cells, and secondly, migrating ASM may have upregulated cell surface expression of fibronectin thus there will be greater ligand expression allowing stronger attachment to occur.
Perlecan domain V binds to ␤ 1 -integrin, which is expressed on ASM (31, 36) and is upregulated in the presence of the proinflammatory cytokine TNF-␣, which is found in greater concentrations in lungs of donors with COPD (21) compared with healthy donors. Thus binding of ASM to domain V may also be enhanced in the COPD lung due to greater levels of TNF-␣ upregulating ASM expressed ␤ 1 -integrin, hence greater binding of migrating ASMC.
It was not unexpected to observe that the domains themselves did not upregulate ASM proliferation or cytokine release as perlecan domains have been shown to not have these effects on other mesenchymal cells (38) .
In conclusion, this study demonstrated that ASMC from COPD donors have enhanced perlecan deposition following stimulation with TGF-␤ 1 that is driven by intracellular SMAD activation and that perlecan has a functional effect of enhancing attachment of COPD ASM via interactions with perlecan domains IV and V. Thus TGF-␤ 1 -induced perlecan deposition in the lungs may be a key process in the development of ASMC hyperplasia in COPD and asthma.
